Navigation Links
Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting
Date:4/15/2008

CALGARY, April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that a poster presentation by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Radiation in Combination with Reolysin for Pediatric Sarcomas" was presented today at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is being held in San Diego, California from April 12-16, 2008.

"The combination of REOLYSIN(R) with radiation is certainly favourable," said Dr. Kolb. "Statistically significant improvements in event-free survival are seen in mice treated with the combination when compared to either therapy alone."

The poster covers preclinical work using reovirus in combination with radiation in mice implanted with pediatric rhabdomyosarcoma and Ewing's sarcoma tumours. The results demonstrated that the combination of reovirus and radiation significantly enhanced efficacy compared to either treatment alone in terms of tumour regression and event-free survival.

"We are very pleased to be working with investigators such as Dr. Kolb," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The work completed by Dr. Kolb and his team supports our ongoing efforts in our human trials with REOLYSIN(R)."

The poster will be available on the Oncolytics website today at http://www.oncolyticsbiotech.com

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiot
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...- Chromatide and Novasep have,extended their partn...and,oligonucleotide synthesis technology. The resu...needs of biotechnology and pharmaceutical industri... for gram to industrial,scale production of high q...p is to combine Chromatide,s experience,in solid p...
(Date:5/16/2008)...etametrix Institute (, http://www.metametrixinstit...ratory Evaluations for Integrative and Functional ...rd S. Lord and J. Alexander Bralley.,This book fol...oratory,Evaluations in Molecular Medicine, publish...rm of Metametrix Inc., a leader in nutritional and...
(Date:5/16/2008)...ogram to Recognize Exemplary Work ...6 /- CURE magazine announced the winn...Award for Oncology Nursing,during a reception at t...ngress. Ortho Biotech Products, L. P. sponsored th...ate unwavering dedication, compassion and,helpfuln...
(Date:5/16/2008).../ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONC...im,results of a Phase II study of intravenous REOL...e lung is available on the American Society of,Cli...org and on the Oncolytics,website at http://www....A Phase II,Study of Intravenous REOLYSIN (Wild-typ...
Breaking Biology Technology:Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology. 2Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology. 3Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology. 4Introducing Laboratory Evaluations for Integrative and Functional Medicine 2CURE Magazine Announces Winner of 2008 Extraordinary Healer Award 2Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting 2
...manufacturer,s product going straight to the lap o...nager, a roofer or a big business, a single-item p...arge inventories. No middle layers, no costly stru...ople or any unnecessary tapes. The supply chain is...nd one quick delivery. , ,It,s like getting a pizz...
...fe sciences nanotechnology company, has received a...r General Medical Sciences. , ,The Small Business ...ment of the company,s proprietary liquid crystal b...s for treatment of cancer. , ,The companys technol...graphy on a nanoscopic scale. By allowing target c...
...r Menards has selected a series of technology so...the company said Wednesday. , ,Menards deployed a ... software and the Teradata Retail Logical Date Mod...arts that could not provide the information busine...ate or out-of-date information, according to the c...
...sities in Germany and India and the University of ... to begin a global master of business administrati... , ,The program further expands upon the Wisconsin...f the state are the borders of the university. , ,...lobal MBA program will begin in June 2006 with 10 ...
Other Biology Technology:Move over B2B, B2C -- it's M2E time 2Move over B2B, B2C -- it's M2E time 3UW-Oshkosh launching Global MBA with schools in Germany, India 2
(Date:5/16/2008)...Changing the sugars attached to a hormone produced... in mice nearly 50 percent, a research group at Wa...s has found. The change appears to alter a reprodu... regulatory system that may one day be used to enh... amount of key reproductive hormones such as estro...
(Date:5/16/2008)...008 New data show that CAPHOSOL ( www.caphosol.co...inful oral mucositis (OM) and improves quality of ...nd radiation therapy. These data will be reported...al podium presentation and one tomorrow as a poste...logy Nursing Society (ONS). These data confirm tha...
(Date:5/16/2008)...dian Journal of Forest Research presents the preli...f the first landscape-scale experiments on how for...ystems. , The Blacks Mountain Interdisciplinary ...dt State University, Oregon State University, U.C....servation Society scientists collaborating in rese...
(Date:5/16/2008)...taining germ-free homes for their children have le...ion of anti-bacterial soaps and cleaning agents. B...s now have come under scrutiny by the EPA and FDA,...ns. , Two closely related antimicrobials, tric...ebacle. Whereas triclosan (TCS) has long captured ...
Breaking Biology News(10 mins):Disabling mouse enzyme increases fertility 2CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients 2CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients 3CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients 4Pioneering landscape-scale research releases first findings 2New study links fate of personal care products to environmental pollution and human health concerns 2New study links fate of personal care products to environmental pollution and human health concerns 3Study shines more light on benefit of vitamin D in fighting cancer 136 1Study shines more light on benefit of vitamin D in fighting cancer 136 2Study shines more light on benefit of vitamin D in fighting cancer 136 3The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank 126 1The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank 126 2The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank 126 3The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank 126 4The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank 126 5Gene Studies of Male Female Differences Often Flawed 135 1Gene Studies of Male Female Differences Often Flawed 135 2Doctors Often Miss High Blood Pressure in Kids 133 1Doctors Often Miss High Blood Pressure in Kids 133 2Doctors Often Miss High Blood Pressure in Kids 133 3
...delivered even in settings of armed conflict, and ... a conflict is over before launching HIV care prog...F) in this week’s PLoS Medicine. , Heather Culbert...s’ experience of providing HIV care, including ant...population in the Democratic Republic of the Congo...
... researchers have uncovered the basis by which pre... have also discovered how the HIV virus works to c... improved vaccines for pregnant women in malaria-r...spread by mosquitoes that kills more than one mill...ostly children, malaria also severely affects preg...
...tute of Biophysics and Nanosystems Research (IBN),...omedical Engineering, Massachusetts Institute of T...ing Curvature and Stability of Monoolein Bilayers ... May 30th issue of the online, open-access journal...erstand the basic science of how lipid-like peptid...
...S. government’s watershed decision to propose list...gered Species Act, the Wildlife Conservation Socie...e Earth’s largest terrestrial predator, not by fol...ice habitat that may drastically shrink as a resul...rs for Cool Bears," WCS will use both current and ...
Other Biology News:Treating HIV in war zones -- Public health emergencies need rapid advice from WHO 2Treating HIV in war zones -- Public health emergencies need rapid advice from WHO 3Treating HIV in war zones -- Public health emergencies need rapid advice from WHO 4HIV and malaria combine to adversely affect pregnant women and their infants 2New designer lipid-like peptide with lipid nanostructures for drug delivery systems 2Want to save polar bears? Follow the ice 2Want to save polar bears? Follow the ice 3
...best-selling first edition of Dr. John Walkers wid...ve been many highly significant developments in pr... attention currently afforded proteins and the rap...y them, Dr. Walker has completed a substantially u...
...Caspase In Situ Assay Kit, Fluorescein is a fluore... in cells undergoing apoptosis. The kit is for res...peutic procedures. CHEMICON®s CaspaTag™ ...h to detect active caspases. The methodology is ba...
... Situ Assay Kit is a fluorescent-based assay for d...optosis. The kit is for research use only. Not for...ICON®s CaspaTag™ Pan-Caspase In Situ Ass...ases. The methodology is based on Fluorochrome Inh...
DTT; 1,4-Dithiothreitol from Roche Applied Science
Biology Products: